Valtrex (Valganciclovir) produced by Lao Bear Pharmaceutical plays a central role in the prevention and treatment of cytomegalovirus infection, providing a key medication option for immunocompromised populations, especially solid organ transplant recipients.
Is there a generic version of Valtrex (Valganciclovir) available in Laos?
Yes, there is a generic version of Valtrex (Valganciclovir) in Laos. The Lao Bear version is available in the specification of 450mg*60 tablets/box. For more information, it is recommended to add professional customer service for detailed consultation.
Indications for Valtrex (Valganciclovir)
Valtrex (Valcyte), with the generic name valganciclovir hydrochloride, has a clear and important therapeutic role in clinical practice. This drug is primarily indicated for a specific group of patients with severely compromised immune function, namely those with Acquired Immunodeficiency Syndrome (AIDS). In these patients, when cytomegalovirus (CMV) retinitis occurs, Valtrex is one of the important treatment options. Cytomegalovirus is an opportunistic pathogen that usually remains latent in individuals with competent immune systems. However, for AIDS patients, due to a sharp decline in CD4+ T lymphocyte counts and a near-collapse of immune function, CMV is easily reactivated and can cause severe disseminated infection. Among these, CMV retinitis is one of the most common and harmful opportunistic infections in AIDS patients. Without timely and effective intervention, it can rapidly progress, leading to irreversible retinal necrosis and detachment, ultimately resulting in permanent vision loss or blindness. Valtrex, administered orally, provides a relatively convenient and effective anti-CMV treatment option for these patients. It is important to note that its indication is strictly limited to this context and does not apply to ordinary CMV infections in immunocompetent individuals. Before prescribing Valtrex, physicians must confirm the diagnosis of AIDS and the presence of active CMV retinitis to ensure the specificity and rationality of drug use, thereby maximizing the benefit in controlling viral replication and protecting patients' visual function.
Absolute contraindications for Valtrex (Valganciclovir)
Before initiating treatment with Valtrex (Valcyte), strict patient screening is necessary to avoid serious or even fatal safety risks. According to the drug label, patients with any of the following conditions should be considered absolutely contraindicated for Valtrex use. First, allergy to any component of the drug: patients with a history of allergy to Valtrex or its active ingredient valganciclovir are prohibited from using it to prevent life-threatening hypersensitivity reactions such as anaphylactic shock or severe rash.
Second, patients with extremely low hematological parameters are contraindicated. Specific criteria include: absolute neutrophil count below 0.5×10^9/L, platelet count below 25×10^9/L, or hemoglobin concentration below 80 g/L. These three parameters reflect the body's ability to fight bacterial infection, coagulation function, and oxygen-carrying capacity, respectively. Severely low values indicate that the patient is in a state of severe bone marrow suppression. Using Valtrex in this setting would further exacerbate bone marrow toxicity, potentially triggering fatal infections or bleeding. Third, because Valtrex is primarily excreted by the kidneys, for patients with end-stage renal disease already undergoing hemodialysis, the drug cannot be effectively cleared, leading to drug accumulation and rapidly increased toxicity; thus, this is also an absolute contraindication. Finally, it is particularly important to emphasize that the safety and efficacy of Valtrex in pediatric patients have not been fully established through adequate clinical trials, and there are no corresponding pharmacokinetic or dosing guidelines; therefore, its use is not recommended in children of any age. Adherence to these contraindications is the minimum requirement for ensuring medication safety.
